Zur Rose Group AG
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. It offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insu… Read more
Zur Rose Group AG (ZRSEF) - Net Assets
Latest net assets as of June 2025: $480.35 Million USD
Based on the latest financial reports, Zur Rose Group AG (ZRSEF) has net assets worth $480.35 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($907.44 Million) and total liabilities ($427.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $480.35 Million |
| % of Total Assets | 52.93% |
| Annual Growth Rate | 9.26% |
| 5-Year Change | -36.04% |
| 10-Year Change | 367.34% |
| Growth Volatility | 49.88 |
Zur Rose Group AG - Net Assets Trend (2009–2024)
This chart illustrates how Zur Rose Group AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zur Rose Group AG (2009–2024)
The table below shows the annual net assets of Zur Rose Group AG from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $340.11 Million | -21.00% |
| 2023-12-31 | $430.53 Million | +22.74% |
| 2022-12-31 | $350.78 Million | -27.66% |
| 2021-12-31 | $484.92 Million | -8.80% |
| 2020-12-31 | $531.74 Million | +31.12% |
| 2019-12-31 | $405.54 Million | -8.58% |
| 2018-12-31 | $443.61 Million | +50.77% |
| 2017-12-31 | $294.22 Million | +183.44% |
| 2016-12-31 | $103.81 Million | +42.64% |
| 2015-12-31 | $72.78 Million | -5.91% |
| 2014-12-31 | $77.35 Million | +5.41% |
| 2013-12-31 | $73.38 Million | -14.47% |
| 2012-12-31 | $85.79 Million | +4.88% |
| 2011-12-31 | $81.80 Million | +3.29% |
| 2010-12-31 | $79.19 Million | -12.14% |
| 2009-12-31 | $90.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zur Rose Group AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1689.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $445.05 Million | 130.85% |
| Other Comprehensive Income | $582.55 Million | 171.28% |
| Total Equity | $340.11 Million | 100.00% |
Zur Rose Group AG Competitors by Market Cap
The table below lists competitors of Zur Rose Group AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Publishing & Media
SHG:601019
|
$497.48 Million |
|
Dark Horse Beijing Technology Co Ltd
SHE:300688
|
$497.50 Million |
|
V V Food & Beverage Co Ltd
SHG:600300
|
$497.63 Million |
|
Guangzhou Hangxin Aviation Technology Co Ltd
SHE:300424
|
$497.64 Million |
|
MCAN Mortgage Corporation
PINK:MAMTF
|
$497.40 Million |
|
MarineMax Inc
NYSE:HZO
|
$497.35 Million |
|
Suzhou Xianglou New Material Co. Ltd.
SHE:301160
|
$497.25 Million |
|
Shenzhen JT Automation Equipment Co Ltd
SHE:300400
|
$497.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zur Rose Group AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 430,532,000 to 340,114,000, a change of -90,418,000 (-21.0%).
- Net loss of 97,253,000 reduced equity.
- Other comprehensive income increased equity by 2,621,000.
- Other factors increased equity by 4,214,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-97.25 Million | -28.59% |
| Other Comprehensive Income | $2.62 Million | +0.77% |
| Other Changes | $4.21 Million | +1.24% |
| Total Change | $- | -21.00% |
Book Value vs Market Value Analysis
This analysis compares Zur Rose Group AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.75x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.24x to 0.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $17.46 | $21.60 | x |
| 2011-12-31 | $25.67 | $21.60 | x |
| 2012-12-31 | $26.85 | $21.60 | x |
| 2013-12-31 | $21.68 | $21.60 | x |
| 2014-12-31 | $22.86 | $21.60 | x |
| 2015-12-31 | $21.44 | $21.60 | x |
| 2016-12-31 | $22.89 | $21.60 | x |
| 2017-12-31 | $56.35 | $21.60 | x |
| 2018-12-31 | $69.87 | $21.60 | x |
| 2019-12-31 | $46.82 | $21.60 | x |
| 2020-12-31 | $58.58 | $21.60 | x |
| 2021-12-31 | $50.28 | $21.60 | x |
| 2022-12-31 | $32.55 | $21.60 | x |
| 2023-12-31 | $36.88 | $21.60 | x |
| 2024-12-31 | $28.84 | $21.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zur Rose Group AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.56%
- • Asset Turnover: 1.31x
- • Equity Multiplier: 2.29x
- Recent ROE (-28.59%) is below the historical average (-10.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 4.95% | 0.80% | 3.36x | 1.83x | $-4.00 Million |
| 2011 | 10.60% | 1.78% | 3.37x | 1.77x | $494.00K |
| 2012 | 7.16% | 1.17% | 1.97x | 3.10x | $-2.44 Million |
| 2013 | -21.07% | -1.70% | 4.05x | 3.07x | $-22.80 Million |
| 2014 | 9.25% | 0.78% | 4.01x | 2.95x | $-581.10K |
| 2015 | 4.73% | 0.41% | 3.57x | 3.21x | $-3.83 Million |
| 2016 | -12.30% | -1.45% | 3.36x | 2.52x | $-23.15 Million |
| 2017 | -12.33% | -3.69% | 2.15x | 1.55x | $-65.64 Million |
| 2018 | -8.79% | -3.23% | 1.66x | 1.64x | $-83.33 Million |
| 2019 | -12.91% | -3.86% | 1.37x | 2.44x | $-92.92 Million |
| 2020 | -25.52% | -9.19% | 1.16x | 2.40x | $-188.87 Million |
| 2021 | -46.55% | -13.07% | 1.36x | 2.62x | $-274.23 Million |
| 2022 | -48.78% | -18.38% | 0.85x | 3.13x | $-206.19 Million |
| 2023 | 19.11% | 8.49% | 1.12x | 2.01x | $39.23 Million |
| 2024 | -28.59% | -9.56% | 1.31x | 2.29x | $-131.26 Million |
Industry Comparison
This section compares Zur Rose Group AG's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $239,198,060
- Average return on equity (ROE) among peers: -6.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zur Rose Group AG (ZRSEF) | $480.35 Million | 4.95% | 0.89x | $497.46 Million |
| Alibaba Health Information Technology Limited (ALBBY) | $1.12 Billion | -18.54% | 0.50x | $12.50 Billion |
| Allstar Health Brands Inc (ALST) | $-9.92 Million | 0.00% | 0.00x | $3.80 |
| Bimi International Medical Inc (BIMI) | $-409.66K | 0.00% | 0.00x | $296.83 |
| Blum Holdings Inc (BLMH) | $-4.74 Million | 0.00% | 0.00x | $8.97 Million |
| China Jo-Jo Drugstores Inc (CJJD) | $26.66 Million | -21.17% | 1.52x | $5.94 Million |
| Clicks Group Ltd (CLCGY) | $1.13 Billion | 41.98% | 2.72x | $4.80 Billion |
| China BCT Pharmacy Group Inc (CNBI) | $134.27 Million | 15.68% | 0.82x | $0.93 |
| Dalrada Financial Corp (DFCO) | $4.40 Million | -81.82% | 0.55x | $1.57 Million |
| Health Advance Inc (HADV) | $-105.34K | 0.00% | 0.00x | $25.40K |
| Healthwarehouse.Com (HEWA) | $-3.10 Million | 0.00% | 0.00x | $741.12 |